Enzolytics concludes plans to advance ITV-1 anti-HIV therapeutics to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the Company.#ENZC https://t.co/gKrePFGYsR
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe $ENZC https://t.co/kn6NQHEw8l
Levels of neutralizing antibodies in recipients of BioNTech/Pfizer vaccine five times LOWER against the DELTA VARIANT than the original Wuhan strain. We had predicted this last year. Address the conserved sites and not chase mutations #ENZC#CURE#Mab#AI
https://t.co/ux7vHUB8p1
Evolutionary biology will cause the virus to continue to mutate. Let us not chase mutations, use AI to identify them, and treat them with targeted Human Monoclonal Antibodies. At Enzolytics we continue to make rapid progress with the CURE. #ENZC#AI#COVID19#HIV B.1.617.2 #mAb
As disclosed on our website we continue to work on therapeutic (CoronaVirus) monoclonal antibodies and phage display anti-SARS-CoV-2 vaccine. We strive to provide regular updates via press releases.
#ENZC $ENZC #COVID19#universal#durable#mAbs#vaccine#EmergingVariants